Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ulixacaltamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Praxis Precision Medicines Submits Ulixacaltamide Hcl Nda
    Praxis Precision Medicines Submits Ulixacaltamide Hcl Nda

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273225/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-of-New-Drug-Application-for-Ulixacaltamide-HCl-in-Patients-with-Essential-Tremor.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Praxis To Present Essential3 Phase 3 Success In Essential Tremor
    Praxis To Present Essential3 Phase 3 Success In Essential Tremor

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272452/0/en/Praxis-to-Showcase-Essential3-the-First-Positive-Phase-3-Program-in-Essential-Tremor-at-AAN-2026.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    Praxis Precision Medicines Updates Corporate Progress
    Praxis Precision Medicines Updates Corporate Progress

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3240986/0/en/Praxis-Precision-Medicines-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    Praxis Precision Pharma Advances After A Key Year Of Achievements
    Praxis Precision Pharma Advances After A Key Year Of Achievements

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216856/0/en/Praxis-Precision-Medicines-Enters-Its-Next-Chapter-Following-a-Pivotal-Year-of-Progress.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Praxis Precision Medicines Gets FDA Breakthrough Status
    Praxis Precision Medicines Gets FDA Breakthrough Status

    29 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/29/3210888/0/en/Praxis-Precision-Medicines-Announces-the-FDA-Has-Granted-Breakthrough-Therapy-Designation-for-Ulixacaltamide-HCl-in-Essential-Tremor.html

    GLOBENEWSWIRE
    29 Dec 2025
    Share Share
    FDA Clears Ulixacaltamide Pre-NDA for Essential Tremor
    FDA Clears Ulixacaltamide Pre-NDA for Essential Tremor

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3200309/0/en/Praxis-Precision-Medicines-Announces-Positive-Pre-NDA-Meeting-with-FDA-for-Ulixacaltamide-in-Essential-Tremor.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.